Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for Sputum Conversion in Pulmonary Tuberculosis
NCT05215990Phase 2Unknown
- Sponsor
- Mahidol University
- Start
- Jan 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of liquid metformin (Aspargo Labs) in pulmonary tuberculosis (TB) (2 arms), sponsored by Mahidol University. Primary endpoint: Acid-fast bacillus sputum conversion ratio from positive to negative at 6 months. Status: unknown.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT05215990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05215990.